FDA Classifies Non-Bug Infection Spotter Device
Published Date: 5/9/2025
Rule
Summary
The FDA is officially putting devices that detect and measure non-microbial signs of localized infections into a special safety category called Class II. This change helps make sure these devices are safe and work well, while also making it easier for patients to get new, helpful tools faster. Companies making these devices will now follow clear rules, which should speed up innovation without extra costs or delays.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
Class II safety rules for infection tests
The FDA is classifying devices that detect and measure non-microbial analytes to aid in the detection and identification of localized human infections into Class II (special controls). This Class II classification, the agency says, will provide a reasonable assurance of safety and effectiveness for those devices.
Faster access, fewer regulatory burdens
The FDA says classifying these devices into Class II will reduce regulatory burdens and put clear special-control rules in place. The agency states this will enhance patients' access to innovative devices and should speed up innovation without extra costs or delays for companies making these devices.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-20063, Request for Nominations for Voting Members of Food and Drug Administration Advisory Committees
The FDA is looking for smart, qualified people to join its advisory committees and help make important decisions about food and drugs. If you have the right skills, you can apply anytime, but get your nomination in by November 30, 2026, for the best chance at current openings. This is a great chance to influence public health without any cost to you!
Previous / Next Documents
Previous: 2025-08143, Medical Devices; Immunology and Microbiology Devices; Classification of the DNA-Based Test To Measure Minimal Residual Disease in Hematological Malignancies
The FDA is officially putting the DNA test that checks for tiny amounts of blood cancer back into a safer, more controlled category called Class II. This means the test will have special rules to make sure it works well and is safe, helping patients get better access to this cool technology faster. Companies making these tests should get ready for these new rules, which aim to keep things safe without slowing down innovation.
Next: 2025-08145, Medical Devices; Immunology and Microbiology Devices; Classification of the Microbial Nucleic Acid Storage and Stabilization Device
The FDA is officially putting microbial nucleic acid storage and stabilization devices into a special safety category called Class II. This means these devices will have clear rules to keep them safe and effective, helping patients get better access to cool new medical tech faster. If you make or use these devices, expect smoother approvals and no surprise costs or delays.